CGTN
23.3.2021 20:21:13 CET | Business Wire | Press release
Forestry reform, reform of the medical and healthcare system, and rural revitalization were highlighted in Chinese President Xi Jinping's second day of his inspection tour in east China's Fujian Province on Tuesday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005995/en/
Visiting the Shaxian District of Sanming City on Tuesday, Xi went to an assets and equity exchange to learn about local efforts to deepen reform of the forest tenure system and a hospital to learn about local reform of the medical and healthcare system.
He also went to a village to inspect work on promoting rural revitalization.
'Lush mountains and lucid waters are valuable assets'
In the past, Chinese farmers were excluded from collective forestry and shared few timber revenues. As a result, they lacked the incentives to protect forests, and timber theft was rampant.
To solve these problems, Fujian Province launched the reform to decentralize the collective forest tenure system in favor of individual (household) management in 2003, which is also considered the start of China's new round of forest tenure reform.
It echoed Xi's instruction to develop forestry as an industry while maintaining its ecological functions when he worked in Fujian.
Xi had visited Sanming City 11 times when he worked in Fujian. During a trip to the city in June 2002, when he was Fujian governor, Xi emphasized that environmental development was of paramount importance.
He said at the time that it might seem that green mountains and lucid waters are of little value, but in the long term, they are valuable assets. He also urged local officials to transform economic growth and avoid wasting resources and damaging the environment.
To carry out Xi's instructions, local authorities further explored a number of reform measures, including taking steps to encourage farmers to transfer their timberland to forest cooperatives and other operators and issuing more loans to forestry businesses to solve their financial problems.
The total output value of forestry reached 114.6 billion yuan in 2019 in Sanming. The city's forest coverage is expected to exceed 80 percent in 2020.
Progress in the reform of the medical and healthcare system
Xi also visited the Shaxian General Hospital in Sanming City to learn about the local medical and healthcare system's reform.
Shaxian General Hospital has jurisdiction over 12 grass-roots branch hospitals and 128 extended village health clinics. Its establishment is also one of the measures to reform the local medical and health system.
Xi has paid close attention to the country's medical reform progress, and praised Sanming's medical advancement at several key meetings.
At the 33rd meeting of the central leading group for deepening overall reform on March 24, 2017, Xi hailed Sanming's experience in medical reform. He said Sanming's medical reform is in the right direction and has produced obvious results, urging promotion of Sanming's practice nationwide.
Shaxian snacks and rural revitalization
Xi has put forward ardent hopes for the development of Shaxian snacks many times, and on Tuesday, he visited the Yubang Village, which is famous for Shaxian snacks, to inspect work on promoting rural revitalization there.
Hailing from Shaxian, popular restaurant chain Shaxian Snacks is renowned for its pork wontons, peanut sauce noodles, and over 100 other local-flavor delicacies.
Starting with a single booth in a street market, the chain now has more than 88,000 chain stores in China and 62 other countries and regions, pulling in a hefty revenue exceeding 50 billion yuan ($7.6 billion).
Thus far, the Shaxian Snacks trademark has been approved by eight countries: Japan, New Zealand, Malaysia, Indonesia, the Philippines, South Korea, Singapore, and Australia. The Shaxian Snacks stores entered 62 countries, including the U.S., Germany, and Portugal. In three hours, the first store in New York sold out and sales revenue of the first store in Tokyo reached nearly $2,000 in 5 hours. After dominating China, it's now aiming at a bigger market and a brighter future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005995/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
